Abstract
Objective. To highlight aspects of malignant ovarian sex cord stromal tumors, effects of treatment, and developments over the past 28 years. Design. Population-based cohort study. Setting. Gynecological departments within the catchment-area of the Munich Cancer Registry and associated with the project group ‘Malignant Ovarian Tumors’ of the Munich Cancer Center. Sample. One hundred and forty-five women with an invasive single sex cord stromal tumor diagnosed between 1978 and 2005. Methods. Overall survival was estimated with the Kaplan–Meier method, relative survival was computed by the ratio of observed to expected survival rate. The impact of age, International Federation of Gynecology and Obstetrics (FIGO)-stage, residual tumor, and chemotherapy was examined by multivariate analysis (Cox regression model). Main outcome measures. Overall and relative survival and multivariate adjusted overall survival. Results. Survival data showed a five-/10-year overall survival of 55.8%/42.8% (relative survival 58.6%/49.2%) for women diagnosed before 1988 and 89.1%/78.3% (relative survival 92.7%/85.2%) for women diagnosed after 1988. After adjustment for age and FIGO-stage, the following hazard ratios and 95% confidence intervals (95% CI) for treatment methods resulted: 3.3 (95% CI 1.5–7.0) for women with compared to women without residual tumor and 2.2 (95% CI 1.2–4.2) for women with chemotherapy compared to women where no chemotherapy was given. Conclusions. Improvements in survival may be attributed to a stage-shift toward more favorable stages at diagnosis and to advances in treatment such as improved surgery without residual tumor. There is no evidence for any benefit of adjuvant chemotherapy. Surgery remains the cornerstone of treatment, yet the benefit of postoperative therapy is still under debate.